The prediction for the M2-stages based on weeks 7 through 10for pen 3 was 1.2% (−0.3–0.03). The prediction for the M2-stagesbased on weeks 7 through 10 for pen 4 was 6.5% (2.4–10.6). Thepredictions for the M2-stages based on weeks 7 through 10 are sig-nificantly different between pens (Fig. 2), although the observedproportions of M2-lesion in the treatment group (pen 4) 5.1%(0.8–9.5) compared to the control group (pen 3) 2.0% (−0.8–4.8)was not significantly different in week 10 (i.e., overlapping confi-dence intervals). Comparing the observed proportions from week13, the observed proportions of M2-lesion in the treatment groupcompared to the control group became significantly different inweek 13 as predicted (i.e., non-overlapping confidence intervals).In addition, the predicted proportions of M0 and M4.1 lesionswere significantly different between pens but these significant differences did not materialize in the observed proportions of week13 (see Fig. 2).